XML 71 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories

The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the years ended December 31, 2024 and 2023:

   2024   2023 
   Year ended December 31, 
   2024   2023 
Preclinical, clinical trial and other costs  $5,450,963   $3,817,669 
Research and development personnel expense(1)   1,818,183    1,981,849 
General and administrative personnel expense(2)   1,981,756    1,737,792 
Administrative and facilities expense(3)   2,800,304    3,919,751 
Interest income, net   (201,088)   (335,541)
Total  $11,850,118   $11,121,520 

 

(1)Research and development personnel costs include employee stock-based compensation expense of $169,414 and $363,956 for the year ended December 31, 2024, and 2023, respectively.

 

(2)General and administrative personnel costs include employee stock-based compensation expense of $186,925 and $387,854 for the year ended December 31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC.

 

(3)Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.